Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy

Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control

(2013) C. Robert et al.   CLINICAL CANCER RESEARCH

CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma

(2012) P. A. Prieto et al.   CLINICAL CANCER RESEARCH

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

(2012) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Diagnosis of Primary CNS Melanoma With Neuroimaging

(2012) Kathryn E. Somers et al.   JOURNAL OF CLINICAL ONCOLOGY

Thanks to referees 2011

(2011)   ANNALS OF ONCOLOGY

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

(2011) Omid Hamid et al.   Journal of Translational Medicine

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study

(2010) S. J. O'Day et al.   ANNALS OF ONCOLOGY

Estimates of cancer incidence and mortality in Europe in 2008

(2010) J. Ferlay et al.   EUROPEAN JOURNAL OF CANCER

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

(2010) Evan M. Hersh et al.   INVESTIGATIONAL NEW DRUGS

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy

(2010) Axel Hoos et al.   SEMINARS IN ONCOLOGY

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

(2009) J. Weber et al.   CLINICAL CANCER RESEARCH

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Current systemic therapy for metastatic melanoma

(2009) Sanjiv S Agarwala   Expert Review of Anticancer Therapy

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

(2009) Jedd D Wolchok et al.   LANCET ONCOLOGY

Anti–Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment

(2008) Lawrence Fong et al.   JOURNAL OF CLINICAL ONCOLOGY

Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials

(2008) Edward L. Korn et al.   JOURNAL OF CLINICAL ONCOLOGY